SynthesisBMC pregnancy and childbirth2025
Effects of co administration of gonadotropins and letrozole during the ovarian stimulation on IVF outcome for poor responders: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Comparative efficacy of modified antagonist protocols combining clomiphene citrate or letrozole for ovarian stimulation in patients with normal ovarian reserve.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLetrozole utilizing, an aromatase inhibitor, has been examined to improve pregnancy rate in poor ovarian response women. Increasing the dose of gonadotropins and enhancement of follicles' sensitivity to androgens, are the possible mechanism of letrozole. This meta-analysis aimed to evaluate the effect of co-administration of letrozole and gonadotropin on IVF/ICSI outcomes in poor ovarian response women.
methodRelevant randomized controlled trials were obtained through search in several databases including PubMed, Scopus, Clinicaltrials.gov, Google scholar, and Cochrane Library. The RCTs investigating the effect of letrozole + gonadotropin versus gonadotropin reporting pregnancy outcome were selected.
resultsAfter analyzing 13 RCTs comprising 1692 patients, letrozole was associated with a reduction in the dose (SMD: -147.96 (-180.49, -115.42), P < 0.01) and duration (SMD: -2.82 (-4.21, -1.42), P < 0.01 of gonadotropin administration. There was no evidence of a difference between groups in the number of retrieved oocytes, clinical pregnancy rate, or live birth rate. A small reduction in the number of transferred embryos was observed (SMD: -0.26 (-0.49, -0.02), P = 0.03), though this finding should be interpreted with caution given heterogeneity across studies. Overall, no significant improvement in reproductive outcomes was demonstrated.
conclusionsDespite the lack of significant improvement in pregnancy and live birth rate in the letrozole group, the dose and duration of gonadotropins decreased. This has the potential to reduce the side effects of gonadotropins. However, further studies are necessary to confirm its safety and whether its use translates into clinically meaningful benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.